A second booster dose resulted in 123,869 fewer hospitalizations and 5,524 fewer deaths versus a single-dose campaign.
No elevated risk for stroke seen after COVID-19 bivalent vaccine receipt
Mar 20, 2024
No evidence was seen for an increased risk for stroke in one- to 21-day or 22- to 42-day windows compared with a 43- to 90-day window after the vaccine.
Higher use of healthcare portal seen during COVID-19 pandemic
Mar 06, 2024
Lower portal activity was linked to older age, female sex and for Hispanic/Latinx, non-Hispanic Black and other race patients.
CDC shortens recommended COVID isolation period
Mar 01, 2024
New guidance issued Friday by the US Centers for Disease Control and Prevention recommends that Americans who test positive for COVID-19 no longer need to routinely stay home for five days.
Cognitive deficits seen in COVID-19 patients regardless of symptom duration
Feb 29, 2024
Compared with those without COVID-19, similar deficits were seen for those in whom symptoms resolved in less than four or at least 12 weeks.
Risk profile IDs COVID-19 patients who will benefit from baricitinib
Feb 26, 2024
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
Cognitive symptoms common with post-COVID-19 condition
Feb 15, 2024
Symptoms were linked to increased odds of at least moderate interference with functioning and lower odds of full-time employment.
Prolonged SARS-CoV-2 risk varies across immunosuppressive conditions
Jan 31, 2024
Severely immunocompromised individuals had greater SARS-CoV-2 evolution and a higher risk for developing resistance against therapeutic mAbs.
Simnotrelvir shortens time to resolution of symptoms in COVID-19
Jan 18, 2024
On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group versus the placebo group.